CN111109359A

CN111109359A - Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application

Info

Publication number: CN111109359A
Application number: CN201911386342.0A
Authority: CN
Inventors: 王刚; 陈卫; 孙姗姗; 乌翛冰; 赵建新; 张灏
Original assignee: Jiangnan University
Current assignee: Jiangnan University
Priority date: 2019-12-29
Filing date: 2019-12-29
Publication date: 2020-05-08
Anticipated expiration: 2039-12-29
Also published as: CN111109359B

Abstract

The pediococcus acidilactici CCFM1105 has good adsorption capacity on PFOS in vitro to reduce PFOS concentration, has good capacity of eliminating diphenyl trinitrophenyl hydrazine free radical, capacity of eliminating hydroxyl free radical and reduction capacity, improves liver enlargement of mice caused by PFOS exposure, improves CAT, SOD and antioxidant capacity levels, improves intestinal flora disorder, reduces abundance of S24-7 family, lactobacillus, bifidobacterium and bacteroides paradoxus in intestinal tracts of the mice, and reduces incidence tendency of diseases such as liver diseases, hypertension, diabetes, obesity and the like.

Description

Multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application

Technical Field

The invention belongs to the technical field of microorganisms, and particularly relates to multifunctional pediococcus acidilactici CCFM1105, fermented food thereof and application thereof.

Background

The perfluoro compound has good thermal stability, chemical stability and biological stability due to the hydrophobic and oleophobic characteristics, and is widely applied to various industries. For use in apparel (e.g., water-resistant, stain-resistant outdoor apparel) and household textiles (e.g., carpets, upholstery, etc.), take-away food containers, personal care products (e.g., dental floss), and fire-fighting foams, among others. In addition, PFOS is one of the final transformation products of many fluorine compounds, and may directly cause harm to human body through environmental exposure, or enter into animal and plant bodies to accumulate in human body through food chain, so it has been receiving more and more attention from researchers. Although PFOS was regarded as a potential contaminant in the early 60's 20 th century, PFOS was detected in human blood and organisms until the 21 st century, and received extensive attention and research on the related aspects. PFOS toxicity and hazards are increasingly recognized, and thus a number of procedures have progressively limited the production and use of PFOS. However, PFOS is still in heavy use in some countries and residual PFOS in the environment may also have a lasting effect on the entire ecosystem for a long time in the future.

The PFOS has various toxic effects such as hepatotoxicity, immunotoxicity, reproductive toxicity, developmental toxicity and neurotoxicity, and the like, and the PFOS can cause hepatomegaly and induce mouse hepatic tissue oxidative stress to cause abnormal free radicals to be increased and possibly cause liver injury, and the PFOS exposure can cause damage of various immune organs of the immune system of aquatic animals and rodents to different degrees, cause atrophic aging of the immune organs such as spleen and spleen, obviously interfere the expression of interleukin in zebrafish, and reduce the lymphocyte proliferation and degeneration of lymphocytes in the exposure experiment of high-dose PFOS to mice, and can reduce the T cell and B cell proliferation of mice, and induce the growth of mouse astrocyte, so the steady state of PFOS-induced growth and edema of mouse astrocyte, and inhibit the growth of mouse astrocyte, so that the growth of mouse can cause abnormal PFOS-induced liver function, blood glucose, blood lipid metabolism and immune function, and immune cells of mice to generate abnormal PFOS-induced liver cell proliferation and kidney tumor.

At present, methods for relieving PFOS toxicity are mostly based on natural chemical substances with high antioxidant activity, such as quercetin, lycium barbarum polysaccharide, morin, trihydroxyisoflavone, lycopene and the like which have relieving effects in research. However, these natural substances are expensive and difficult to obtain, and in addition, the potential hazard to the human body from the large intake is unknown due to the human body's tolerance. Therefore, it is clearly necessary to find an effective way to effectively alleviate PFOS toxicity without any other possible deleterious effects on the human body.

Disclosure of Invention

This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.

As one aspect of the invention, the invention overcomes the defects in the prior art, and provides pediococcus acidilactici CCFM1105 with the collection number of GDMCC No: 60899.

as another aspect of the present invention, the present invention overcomes the disadvantages of the prior art and provides a fermented food: the fermented food is prepared by fermenting and producing Pediococcus acidilactici CCFM1105, and the fermented food comprises solid food, liquid food and semi-solid food.

As a preferable embodiment of the fermented food of the present invention: the fermented food comprises dairy products, bean products and fruit and vegetable products, and the dairy products comprise milk, sour cream and cheese; the fruit and vegetable products comprise cucumber, carrot, beet, celery and cabbage products.

As another aspect of the invention, the invention overcomes the defects in the prior art and provides the application of pediococcus acidilactici CCFM1105 in preparing non-colonized probiotics in vivo.

As another aspect of the invention, the invention overcomes the defects in the prior art and provides the application of pediococcus acidilactici CCFM1105 in preparing the medicines and health products for relieving the toxic effect of PFOS, and resisting liver diseases, hypertension, diabetes, obesity and the like.

As a preferable scheme of the application, the pediococcus acidilactici CCFM1105 has good adsorption capacity on PFOS in vitro to reduce PFOS concentration, has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), capacity of removing hydroxyl free radical and reducing capacity, improves liver enlargement caused by PFOS exposure, reduces the content of TNF- α in liver, reduces the content of glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST) and alkaline phosphatase (ALP) in serum, improves the levels of CAT, SOD and antioxidant capacity, improves intestinal flora disorder, reduces the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in intestinal tract, and reduces the incidence tendency of diseases such as liver disease, hypertension, diabetes and obesity.

As another aspect of the invention, the invention overcomes the defects in the prior art and provides the application of the fermented food in functional foods for relieving PFOS toxicity, resisting liver diseases, resisting hypertension, resisting diabetes and resisting obesity.

The pediococcus acidilactici CCFM1105 has good adsorption capacity on PFOS in vitro to reduce PFOS concentration, has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), capacity of removing hydroxyl free radical and reduction capacity, improves hepatomegaly caused by PFOS exposure, reduces the content of TNF- α in liver, reduces the content of alanine Aminotransferase (ALT), glutamic oxaloacetic transaminase (AST) and alkaline phosphatase (ALP) in serum, improves the levels of CAT, SOD and antioxidant capacity, improves intestinal flora disorder, reduces the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in intestinal tract, reduces the incidence tendency of diseases such as liver diseases, hypertension, diabetes and obesity, and the like.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:

FIG. 1 is a schematic diagram of the concentration change of PFOS after the bacterial strain is resuspended in PFOS with the concentration of 20mg/L in vitro, passes through a 0.22 mu m water-based filter membrane, enters an ultra-high performance liquid chromatography-mass spectrometer after being shaken at 37 ℃ and 200rpm for 12 hours, and is adsorbed.

FIG. 2 shows that the strain of the present invention has the capacity of eliminating diphenyl trinitrophenyl hydrazine free radical (DPPH) and hydroxyl radical eliminating capacity and reducing capacity.

FIG. 3 is a graph showing the change in specific gravity of the liver of mice exposed to PFOS 15 days after the intervention of the strain of the present invention. With the different letter representations having significant differences.

FIG. 4 is a graph showing the levels of ALP, ALT and AST in the serum of mice exposed to PFOS 15 days after the intervention of the strain of the present invention. With the different letter representations having significant differences.

FIG. 5 is a graph showing the changes of CAT, SOD and antioxidant ability in the liver of mice exposed to PFOS 15 days after the intervention of the strain of the present invention. With the different letter representations having significant differences.

FIG. 6 is a diagram showing the exposure of mice to PFOS and the tumor necrosis factor α in the liver of the mice 15 days after the intervention of the strain of the present invention, wherein different letters represent significant differences.

FIG. 7 is a diagram showing the diversity change of the mouse intestinal flora α after the mouse is exposed to PFOS 15 days after the intervention of the strain of the invention, wherein different letters represent significant differences.

FIG. 8 is a graph showing the change in the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Bacteroides (Parabacteroides) in the intestine of mice exposed to PFOS 15 days after the intervention with the strain of the present invention; with the different letter representations having significant differences.

Detailed Description

In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with examples are described in detail below.

In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.

Furthermore, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.

The Pediococcus acidilactici (Pediococcus ethanolidurans) CCFM1105 is preserved in the microbial strain preservation center of Guangdong province in 11-22.2019, with the preservation address of No. 59 floor 5 of Michelia furiosu No. 100 college of Guangzhou city, and the preservation number of the microbial research institute of Guangdong province being GDMCC No: 60899.

the pediococcus acidilactici has the following biological properties:

(1) the characteristics of the thallus are as follows: gram-positive, spherical cell, diameter of 0.8-1.0 μm, no flagellum, no spore;

(2) colony characteristics: the colony is milky white, the edge is neat, round, convex and non-transparent, and the surface is moist and smooth;

(3) growth characteristics: the minimum growth temperature of the strain is 15 ℃, the maximum growth temperature is 45 ℃, the strain grows optimally at the temperature of 35-37 ℃, the optimum growth pH is 6.5, and the strain enters a stable period after being cultured for 18 hours;

(5) the in vitro has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), hydroxyl free radical removing capacity and reducing capacity;

(6) pediococcus acidilactici CCFM1105 can obviously improve the hepatomegaly of the mice exposed by PFOS;

(7) pediococcus acidilactici CCFM1105 can significantly reduce the levels of ALP, ALT and AST in the serum of mice exposed by PFOS;

(8) pediococcus acidilactici CCFM1105 can obviously improve the levels of CAT, SOD and antioxidant capacity in the liver of a PFOS-exposed mouse.

(9) The pediococcus acidilactici CCFM1105 can obviously reduce the content of TNF- α in the liver of a mouse exposed by PFOS;

(10) the pediococcus acidilactici CCFM1105 obviously reduces the abundance of S24-7 family, Lactobacillus, Bifidobacterium and Parabacteroides in intestinal tracts of mice, improves the intestinal flora disorder caused by PFOS exposure, and reduces the incidence tendency of diseases such as liver diseases, hypertension, diabetes, obesity and the like.

The extraction method of the pediococcus acidilactici CCFM1105 comprises the following steps:

separating and screening lactic acid bacteria:

(l) Collecting pickle samples, and enriching the samples in a culture medium containing sorbitol GM17 at 35 ℃ for 12 h;

(2) performing gradient dilution on the enriched sample, then coating the enriched sample on a GM17 solid plate added with 0.02% of olcresol purple, and culturing for 24-48 h;

(3) selecting single bacterial colony with obvious color changing circle and according with the basic morphology of lactobacillus, carrying out plate streaking purification, and screening and separating out lactobacillus;

(4) and culturing the single colony in a liquid GM17 culture solution for 24h, performing gram staining, and selecting gram-positive bacteria for subsequent tests.

(II) preliminary identification of lactic acid bacteria: caldolytic ring assay

(l) Culturing the lactic acid bacteria obtained by screening in the step (I) in a liquid sorbitol GM17 culture solution for 24h, and then centrifuging l mL of culture at 8000rpm for 2 min;

(2) with 0.05M KH₂PO₄Washing the solution twice;

(3) resuspending the resulting pellet and streaking on sorbitol GM 17-0.75% CaCO₃Culturing for 24 hours on the solid culture medium;

(4) selecting bacterial colonies which are obvious in calcium-dissolving ring, round in convex surface, fine, dense and white in color and sterile filaments, and preliminarily determining to be cocci when the bacteria are spherical after gram staining and observed by a microscope.

(III) molecular biological identification of lactic acid bacteria:

(l) Extracting a single-bacterium genome:

A. culturing the lactic acid bacteria obtained by screening in the step (II) overnight, taking l mL of the overnight-cultured bacterial suspension into a 1.5mL centrifuge tube, centrifuging at 10000rpm for 2min, and removing the supernatant to obtain thalli;

B. purging the thalli with l mL of sterile water, centrifuging at 10000rpm for 2min, and removing the supernatant to obtain the thalli;

C. adding 200 μ LSDS lysate, and water-bathing at 80 deg.C for 30 min;

D. adding 200 μ L of phenol-chloroform solution into the thallus lysate, wherein the phenol-chloroform solution comprises Tris saturated phenol, chloroform and isoamylol at a volume ratio of 25:24:1, mixing, centrifuging at 12000rpm for 5-10min, and collecting 200 μ L of supernatant;

E. adding 400 μ L of glacial ethanol or glacial isopropanol into 200uL of supernatant, standing at-20 deg.C for 1h, centrifuging at 12000rpm for 5-10min, and discarding the supernatant;

F. adding 500 μ L70% (volume percentage) of glacial ethanol, resuspending the precipitate, centrifuging at 12000rpm for 1-3min, and discarding the supernatant;

drying in an oven at G.60 ℃ or naturally airing;

H.50μLddH₂re-dissolving the precipitate with O for PCR;

(2)16S rDNAPCR

A. bacterial 16S rDNA50 μ LPCR reaction system:

10 × Taq buffer, 5 μ L; dNTP, 5. mu.L; 27F, 0.5 μ L; 1492R, 0.5 μ L; taq enzyme, 0.5. mu.L; template, 0.5 μ L; ddH₂O，38μL。

PCR conditions:

95℃5min；95℃10s；55℃30s；72℃30s；step2-4 30×；72℃5min；12℃2min；

(3) preparing 1% agarose gel, mixing the PCR product with 10000 × loading buffer, loading the sample by 5 μ L, running at 120V for 30min, and performing gel imaging;

(4) and (3) sequencing the PCR product of the 16S rDNA, searching and comparing similarity of the obtained sequence result in GeneBank by using BLAST, selecting a newly discovered strain identified as the strain belonging to pediococcus acidilactici according to the sequencing result, and preserving at-80 ℃ for later use.

Example 1: pediococcus acidilactici CCFM1105 has good PFOS adsorption capacity

The bacterial adsorption is used for purifying and activating the pediococcus acidilactici CCFM1105, inoculating the pediococcus acidilactici CCFM1105 into an MRS liquid culture medium according to the inoculation amount of 1% (v/v), and culturing for 12h at 37 ℃. Then centrifuging at 8000r/min for 5min to collect thallus, collecting precipitate, cleaning with physiological saline, centrifuging at 8000r/min for 5min, and removing precipitate to obtain viable thallus cell, i.e. wet thallus. The wet cells were resuspended in a solution of 20mg/L PFOS to a final cell concentration of 1g dry cells/L (the wet cells were resuspended in ultrapure water containing no PFOS as a blank control). The pH of the PFOS solution containing the inoculum solution was rapidly adjusted to 3.0 using 0.1M NaOH or HCl solution, and the effect of the ionic strength on PFOS adsorption was negligible by adding a small amount of NaOH or HCl (less than 0.5 ml). Subsequently, a 250ml conical flask containing 100ml of the sample solution was subjected to shake culture at 37 ℃ and 200rpm, and after 12 hours, sampling was performed, and 2 parallel experiments were averaged.

Measurement of PFOS adsorption amount: after the adsorption experiment, the sample was centrifuged at 8000r/min for 5min and filtered with a 0.22 μm water membrane, PFOS concentration was measured by UPLC-MS with Waters SYNAPT MS system using an acquisition UPLC BEH c18 column (2.1X 100mm, 1.7 μm, Waters Co.), column temperature 35 ℃ and sample size 1 μ L. Gradient washing was carried out using 100% (v/v) acetonitrile solution (solution A) and 0.1% (v/v) aqueous formic acid solution (solution B) as eluents at a flow rate of 0.3 mL/min.

TABLE 1 gradient elution conditions

t/min	0-0.5	0.5-5.0	5.0-7.0	7.0-7.5
					Ratio of solvent A	70％	70-100％	100％	100-70％

Mass spectrum conditions: the ionization source is an ESI source; MRM detection; MS + detection; capillary (Capillary); 3.0 kV; conc (vertebral body): 40.00V; source Temperature: 120 ℃; desolvation (Desolvation) temperature: 400 ℃; conc Gas Flow: 50L/h; desolvation Gas Flow: 700L/h, gas flow rate of 0.1 ml/min; proton ratio scan range: 100-; scan time 1s, interval 0.061 s. The results were analyzed with MassLynxV4.1(Waters Corp.); and calculating the PFOS adsorption amount of the lactic acid bacteria according to the concentration difference of the PFOS before and after adsorption. The results are shown in FIG. 1, and the adsorption rate of CCFM1105 to PFOS of 20mg/L is 74.26% + -3.47%.

Example 2: the pediococcus acidilactici CCFM1105 has good capacity of removing diphenyl trinitrophenyl hydrazine free radical (DPPH), hydroxyl free radical removing capacity and reducing capacity in vitro;

after 1mL of Pediococcus acidilactici CCFM1105 whole cell suspension and 1mL of freshly prepared DPPH absolute ethanol solution (0.2mmol/L) are fully mixed, the mixture is subjected to a light-shielding reaction at 37 ℃ for 30 min. DPPH was mixed with PBS (pH7.2) as a control sample, and cultured under the same conditions. After centrifugation at 7000 Xg for 10min, the absorbance was measured at 517nm and the ability of the lactic acid bacteria to scavenge DPPH radicals was calculated according to the following formula:

DPPH radical clearance (%) [1-a517 (sample)/a 517 (control) ] × 100%.

1mL1, 10-phenanthroline 1mLPBS (pH7.2), 1mL Pediococcus acidilactici CCFM1105 whole cell suspension or and 1mLFeSO4 were mixed well (referred to as "mixture 1"). To "mixture 1" was added 1mLH₂O₂The absorbance was measured at 536nm in a water bath at 37 ℃ for 1.5h and expressed as A536 (sample). The whole cell suspension in "mixture 1" was replaced with the same volume of distilled water, cultured under the same conditions and tested, and denoted as A536 (blank). H to "mixture 1" is added₂O₂The cells were cultured under the same conditions and examined by changing to the same volume of distilled water, and designated as A536 (control). The ability of lactic acid bacteria to scavenge hydroxyl radicals is calculated according to the following formula:

hydroxyl radical clearance (%) - [ a536 (sample) -a536 (blank) ]/[ a536 (control) -a536 (blank) ] × 100%

0.5mL of Pediococcus acidilactici CCFM1105 whole cell suspension was mixed with the same volume of potassium ferricyanide (1%) and PBS buffer (pH6.6), and the mixture was shaken to homogenize the system. Distilled water was mixed with potassium ferricyanide and PBS as a blank control. The mixed system was incubated at 50 ℃ for 20min, rapidly cooled and 0.5mL of 10% trichloroacetic acid was added. After centrifugation at 2000 Xg for 5min, 1mL of the supernatant was mixed with 1mL of 0.1% ferric chloride and reacted for 10 min. The absorbance was then measured at a wavelength of 700nm and Cysteine (Cysteine) was used as a standard for characterizing the reducing power. The results of the experiment are shown in FIG. 2.

Example 3: the pediococcus acidilactici CCFM1105 can obviously improve 24 male C57BL/6J mice with 6-week-old liver enlargement of PFOS exposed mice, and after adapting to the environment for one week, the mice are randomly divided into four groups according to the weight: blank control group, model group, quercetin intervention group, pediococcus acidilactici CCFM1105 intervention group, each group contains 6 mice, and animal grouping and processing method are shown in Table 2.

TABLE 2 animal experiment grouping and processing method

The mice in example 2 were weighed on day 31, then euthanized, bled from the eye sockets, and the liver was removed and weighed wet to calculate organ coefficients, which were calculated according to the following formula:

liver organ coefficient ═ liver wet weight (g)/weight of euthanasia mice (100g)

The experimental results are shown in fig. 3, and the results show that the mice liver enlargement caused by PFOS exposure can be obviously relieved by taking pediococcus acidilactici CCFM 1105.

Example 4: pediococcus acidilactici CCFM1105 can obviously reduce the levels of ALT, ALP and AST in serum of mice exposed by PFOS

Blood in example 3 is taken and stood for one hour, then 3500r/min is carried out, centrifugation is carried out for 15min, and serum is taken for testing. And detecting the contents of ALT, ALP and AST in the serum by using a full-automatic biochemical analyzer. ALT, AST, as a non-specific functional enzyme in the hepatocyte cytoplasm and mitochondria, is released into the blood when hepatocytes are disrupted. ALP is normally excreted by the liver and enters the blood stream via the lymphatic channels and the hepatic sinuses when there is damage to the liver. The experimental result shows (figure 4) that the content of ALT, ALP and AST in the serum of mice exposed by PFOS can be obviously reduced by taking pediococcus acidilactici CCFM 1105. The result shows that the damage of the structure and the function of the liver cell membrane of the mouse caused by PFOS can be obviously relieved by taking the pediococcus acidilactici CCFM 1105.

Example 5: pediococcus acidilactici CCFM1105 can obviously reduce the level of MDA and GSH in liver of mice exposed by PFOS

The mouse liver in example 3 was taken to prepare a 10% homogenate, the liver was accurately weighed according to the weight (g): volume (ml): 1:9 ratio, 9 volumes of physiological saline was added, mechanical homogenization was performed in an ice water bath, cells were sufficiently disrupted, 5000r/min was performed, centrifugation was performed for 10 minutes, and the supernatant was taken for measurement. The levels of SOD, CAT and antioxidant capacity T-AOC in the liver were determined according to the kit provided by Nanjing's built kit. CAT is mainly present in peroxisomes and is responsible for H₂O₂Reduction of (a) and oxidative protection of unsaturated fatty acids in cell membranes. SOD is important antioxidant enzyme in vivo, and has important scavenging effect on ROS. Antioxidant capacity may indicate the level of oxidative stress the body treats. Experimental results show that (figure 5) the levels of CAT, SOD and antioxidant capacity in the liver of a mouse exposed by PFOS can be obviously improved by taking pediococcus acidilactici CCFM 1105. The result shows that the pediococcus acidilactici CCFM1105 can effectively improve the liver oxidative stress injury caused by PFOS.

Example 6 Pediococcus acidilactici CCFM1105 can significantly reduce the content of TNF- α in the liver of PFOS-exposed mice

The mouse liver in example 3 is taken to prepare 10% homogenate, the liver is accurately weighed according to the weight (g): the volume (ml): 1:9 ratio, 9 times of normal saline is added, mechanical homogenate is carried out under the condition of ice water bath, cells are fully crushed, 5000r/min is carried out, centrifugation is carried out for 10 minutes, supernatant liver homogenate is taken for determination, the content of the cell factor TNF- α in the liver is determined according to the specification of an ELISA kit (RD), and the experimental result shows that the inflammatory injury of the mouse liver caused by PFOS exposure can be obviously improved by taking the pediococcus acidilactici CCFM1105 (figure 6).

Example 7: the pediococcus acidilactici CCFM1105 can obviously reduce the abundance of S24-7 family, Lactobacillus, Bifidobacterium and Parabacteroides in the intestinal tract of mice exposed by PFOS, improve the intestinal tract disorder caused by PFOS exposure, and reduce the tendency of diseases such as liver disease, hypertension, diabetes, obesity and the like.

Fresh feces from the mice on day 31 of example 3 were taken and total DNA was extracted from the fecal samples of the mice using the feces kit from MP. The specific operation steps are mainly carried out according to the kit instructions. A V3-V4 region fragment of 16S rDNA is amplified by taking a mouse fecal genome as a template and taking an upstream primer 520F (5 '-AYTGGGYDTAAAGNG-3') and a downstream primer 802R (5 '-TACNVGGGTATCTAATCC-3') as primers, and the length of a target fragment is about 247 bp. And after the PCR reaction is finished, performing electrophoresis again on all the PCR samples with the observed target bands, preparing 2.0% agarose gel, performing electrophoresis for 40min under the condition of 120V, and after the gel is run, rapidly cutting the target bands under an ultraviolet lamp. The recovery of the target band Gel was carried out according to the QIAquick Gel Extraction Kit Gel recovery Kit instructions. The DNA concentration of the Sample is detected according to a Qubit DNA3.0 Kit, then a library is constructed according to a TurSeq DNA LT Sample Preparation Kit and the description thereof, and finally the concentration is determined on an Illumina Miseq sequencer according to a MiSeq Regent Kit and the description thereof. After the sequencing is finished, single sequences with the sequence length less than 200bp, primer sequences and non-splicing sequences are removed, and the single sequences are overlapped according to the basic groups>10bp standard splicing sequence without mismatch. Defining the sequence with similarity greater than 97% as a classification Unit (OTU), by RibosolDatabase Project (RDP)

α -diversity is characterized by chao1 and updated species indices, the results (figure 7) show that the intestinal flora α diversity of model mice is increased, indicating that PFOS exposure is accompanied by a certain degree of intestinal disorderIntestinal disorders.

After PFOS infection, the abundances of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in feces are increased, while the abundances of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in PFOS infected mice can be significantly reduced by taking Pediococcus acidilactici CCFM11105 (FIG. 8); s24-7 is highly localized in the gastrointestinal tract of warm-blooded animals, gram-negative non-motile anaerobic microorganisms, capable of fermenting a wide variety of carbohydrates, and is involved in the development of nonalcoholic fatty liver disease and hypertension. Lactobacillus (Lactobacillus) is a part of normal gastrointestinal tract and genitourinary apparatus, is common probiotics, and has the condition that the abundance of PFOS model group and contamination model is increased in the lactic acid bacteria prevention experiment, and the lactic acid bacteria may have negative feedback regulation after PFOS exposure. Bifidobacteria (bifidobacteria) are widely present in the human and animal habitat, such as the digestive tract, vagina and oral cavity, and one of the important components of the human and animal intestinal flora can be used as probiotics in the fields of food, medicine and feed. Under normal conditions, intestinal microorganisms in the human body form a relatively balanced state. After PFOS contamination, intestinal microbial balance is disrupted, resulting in intestinal flora disturbance, and certain intestinal microorganisms such as clostridium perfringens proliferate excessively in the intestinal tract and produce harmful substances such as ammonia, amines, hydrogen sulfide, skatole, indole, nitrite, bacterial toxins, and the like, thereby further affecting health conditions. At this time, Bifidobacterium (Bifidobacterium) can generate feedback regulation, increase abundance to inhibit the growth of harmful bacteria, resist the infection of foreign pollutants, synthesize vitamins required by human body, promote the absorption of mineral substances by human body, generate organic acids such as acetic acid, propionic acid, butyric acid and lactic acid to stimulate intestinal peristalsis, promote defecation, prevent constipation and intestinal putrefaction, purify intestinal environment, decompose carcinogenic substances, stimulate the immune system of human body, and improve disease resistance. Bacteroides paraBacteroides (Parabacteroides) is one of human core flora, and in vivo and in vitro experiments show that the Bacteroides Parabacteroides (Parabacteroides) has cholic acid conversion function, can also produce a large amount of succinic acid, can activate an intestinal FXR signal path, improve lipid metabolism disorder, repair intestinal walls and activate intestinal gluconeogenesis, thereby regulating appetite, promoting liver glycogen synthesis and improving host glycometabolism disorder. In addition, the research shows that the content of the Parabacteroides paradise (Parabacteroides) is reduced, and the tendency of the body to suffer from diseases such as obesity, non-alcoholic fatty liver disease, diabetes mellitus and the like is increased. The results show that the pediococcus acidilactici CCFM1105 has the functions of regulating intestinal flora, regulating immunity and intestinal barrier, and reducing the occurrence of liver diseases, hypertension, diabetes and obesity on the basis of relieving PFOS toxicity.

Example 8: fermented food of the pediococcus acidilactici CCFM1105 is prepared by the pediococcus acidilactici CCFM1105 of the invention

Selecting fresh vegetables, washing, juicing, carrying out high-temperature instant sterilization, carrying out high-temperature heat sterilization at 140 ℃ for 2 seconds, immediately cooling to 37 ℃, and inoculating the fermentation agent of the Pediococcus acidilactici CCFM1105 microbial inoculum prepared by the invention to ensure that the concentration of the fermentation agent reaches 10⁶More than CFU/mL, and storing at 4 ℃ in a refrigerated way, thus obtaining the fruit and vegetable beverage containing the pediococcus acidilactici CCFM1105 viable bacteria.

The invention can be used for preparing other fermented foods by fermenting the pediococcus acidilactici CCFM1105, wherein the fermented foods comprise solid foods, liquid foods and semi-solid foods. The fermented food comprises dairy products, bean products and fruit and vegetable products, wherein the dairy products comprise milk, sour cream and cheese; the fruit and vegetable products comprise cucumber, carrot, beet, celery and cabbage products.

The pediococcus acidilactici CCFM1105 has a good adsorption effect on PFOS in vitro, the pediococcus acidilactici CCFM1105 has a high antioxidation effect in removing diphenyl trinitrophenyl hydrazine free radical (DPPH), removing hydroxyl free radical and reducing capacity, the pediococcus acidilactici CCFM1105 obviously improves hepatomegaly caused by PFOS exposure, the content of TNF- α in livers after PFOS exposure is obviously reduced, the pediococcus acidilactici CCFM1105 obviously reduces the content of glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST) and alkaline phosphatase (ALP) in blood serum after PFOS exposure, the pediococcus acidilactici CCFM1105 increases the content of CAT and GSH in livers and improves the antioxidation capacity of the livers, and the pediococcus acidilactici CCFM1105 can improve the disturbance of intestinal flora after PFOS exposure and reduce the tendency of occurrence of diabetes mellitus, constipation, high blood pressure, high abundance and obesity of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and paranoid (paranoid).

In a PFOS model mouse experiment, the liver enlargement of a mouse caused by PFOS exposure can be obviously improved by taking the pediococcus acidilactici CCFM1105, the content of TNF- α in the liver of the PFOS exposed mouse can be obviously reduced by taking the pediococcus acidilactici CCFM1105, the content of ALT, AST and ALP in the serum of the PFOS exposed mouse can be reduced by taking the pediococcus acidilactici CCFM1105, the content of CAT and GSH in the liver can be increased by taking the pediococcus acidilactici CCFM1105, the antioxidation capability of the liver can be improved, the intestinal flora disorder of the PFOS exposed mouse can be improved, the S24-7 family, Lactobacillus (Lactobacillius), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in the intestinal tract can be reduced, the occurrence of liver diseases, constipation, hypertension, diabetes and obesity can be reduced by taking the pediococcus acidilactici 1105.

The invention screens out the probiotics which have high adsorption capacity to the PFOS, are not colonized in a human body and have high oxidation resistance, can inhibit the oxidative stress caused by the PFOS, and can fundamentally remove the PFOS in the human body. The pediococcus acidilactici CCFM1105 can be used for preparing foods, health products and medicines for relieving PFOS toxicity, and has very wide application prospect.

It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.

Claims

1. Pediococcus acidilactici CCFM1105 with the collection number GDMCC No: 60899.

2. a fermented food product characterized by: the fermented food is prepared by fermenting and producing Pediococcus acidilactici CCFM1105, and the fermented food comprises solid food, liquid food and semi-solid food.

3. The fermented food product according to claim 2, wherein: the fermented food comprises dairy products, bean products and fruit and vegetable products, wherein the dairy products comprise milk, sour cream and cheese; the fruit and vegetable products comprise cucumber, carrot, beet, celery and cabbage products.

4. Application of pediococcus acidilactici CCFM1105 in preparing non-colonized probiotics in vivo.

5. The pediococcus acidilactici CCFM1105 is applied to the preparation of drugs and health care products for relieving the toxic effect of PFOS, resisting liver diseases, hypertension, diabetes and obesity.

6. The use of claim 5, wherein Pediococcus acidilactici CCFM1105 has good PFOS adsorption capacity in vitro to reduce PFOS concentration, good diphenyl trinitrophenyl hydrazine free radical (DPPH) scavenging ability and reducing ability, liver enlargement due to PFOS exposure, TNF- α content in liver reduction, serum glutamate pyruvate transaminase (ALT), glutamate oxaloacetate transaminase (AST), alkaline phosphatase (ALP) content reduction, and CAT, SOD and antioxidant activity level increase.

7. Use according to claim 6, characterized in that: the pediococcus acidilactici CCFM1105 can also improve intestinal flora disorder, reduce the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in intestinal tracts, and reduce the incidence tendency of diseases such as liver disease, hypertension, diabetes and obesity.

8. Use of the fermented food according to claim 2 or 3 for functional foods for relieving PFOS toxicity, anti-liver diseases, anti-hypertension, anti-diabetes, anti-obesity.

9. The use of claim 8, wherein Pediococcus acidilactici CCFM1105 has good PFOS adsorption capacity in vitro to reduce PFOS concentration, good diphenyl trinitrophenyl hydrazine free radical (DPPH) scavenging ability and reducing ability, improvement of liver enlargement caused by PFOS exposure, reduction of TNF- α content in liver, reduction of alanine Aminotransferase (ALT), aspartate Aminotransferase (AST) and alkaline phosphatase (ALP) content in serum, and increase of CAT, SOD and antioxidant ability.

10. The use of claim 9, wherein: the pediococcus acidilactici CCFM1105 can also improve intestinal flora disorder, reduce the abundance of S24-7 family, Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium) and Parabacteroides (Parabacteroides) in intestinal tracts, and reduce the incidence tendency of diseases such as liver disease, hypertension, diabetes and obesity.